Bone Repair Cells (BRCs)
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Single Level Posterolateral Spinal Fusion
Conditions
Single Level Posterolateral Spinal Fusion
Trial Timeline
Apr 1, 2006 → Oct 1, 2008
NCT ID
NCT00797550About Bone Repair Cells (BRCs)
Bone Repair Cells (BRCs) is a phase 1/2 stage product being developed by Vericel for Single Level Posterolateral Spinal Fusion. The current trial status is terminated. This product is registered under clinical trial identifier NCT00797550. Target conditions include Single Level Posterolateral Spinal Fusion.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00797550 | Phase 1/2 | Terminated |
Competing Products
2 competing products in Single Level Posterolateral Spinal Fusion
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HSC835 | Novartis | Phase 2 | 52 |
| Dexmedetomidine | Orion Corporation | Phase 3 | 74 |